FTBMT | CAS#1358575-02-6 | GPR52 agonist

MedKoo Cat#: 561779 | Name: FTBMT

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FTBMT is a selective GPR52 agonist. It demonstrates antipsychotic-like and procognitive effects in rodents and has revealed a potential therapeutic agent for schizophrenia.

Chemical Structure

FTBMT

CAS#1358575-02-6

Theoretical Analysis

MedKoo Cat#: 561779

Name: FTBMT

CAS#: 1358575-02-6

Chemical Formula: C19H16F4N4O

Exact Mass: 392.1260

Molecular Weight: 392.35

Elemental Analysis: C, 58.16; H, 4.11; F, 19.37; N, 14.28; O, 4.08

Price and Availability

Size	Price	Availability
10mg	USD 350.00	2 Weeks
25mg	USD 650.00	2 Weeks
50mg	USD 950.00	2 Weeks
100mg	USD 1,550.00	2 Weeks
200mg	USD 2,650.00	2 Weeks
500mg	USD 3,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

FTBMT; TP-024; TP024; TP 024

IUPAC/Chemical Name

4-(3-(3-Fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide

InChi Key

TYXSIXOYTBHZFA-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H16F4N4O/c1-10-5-15(3-4-16(10)18(24)28)27-11(2)25-17(26-27)8-12-6-13(19(21,22)23)9-14(20)7-12/h3-7,9H,8H2,1-2H3,(H2,24,28)

SMILES Code

O=C(N)C1=CC=C(N2N=C(CC3=CC(C(F)(F)F)=CC(F)=C3)N=C2C)C=C1C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

FTBMT is a selective GPR52 agonist with an EC50 of 75 nM.

In vitro activity:

FTBMT increased intracellular cAMP levels in CHO cells expressing human, mouse, or rat GPR52, with pEC50 values of 7.03 ± 0.04, 6.85 ± 0.02, and 6.87 ± 0.02, respectively (Fig. 1B). Reference: J Pharmacol Exp Ther. 2017 Nov;363(2):253-264. https://pubmed.ncbi.nlm.nih.gov/28851764/

In vivo activity:

FTBMT inhibited MK-801-induced hyperactivity, an animal model for acute psychosis, without causing catalepsy in mice. The c-fos expression also revealed that FTBMT preferentially induced neuronal activation in the shell of the Nac compared with the striatum, thereby supporting its antipsychotic-like activity with less catalepsy. Furthermore, FTBMT improved recognition memory in a novel object-recognition test and attenuated MK-801-induced working memory deficits in a radial arm maze test in rats. Reference: J Pharmacol Exp Ther. 2017 Nov;363(2):253-264. https://pubmed.ncbi.nlm.nih.gov/28851764/

	Solvent	mg/mL	mM
Solubility
	DMSO	69.6	177.44

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 392.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Nishiyama K, Suzuki H, Harasawa T, Suzuki N, Kurimoto E, Kawai T, Maruyama M, Komatsu H, Sakuma K, Shimizu Y, Shimojo M. FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia. J Pharmacol Exp Ther. 2017 Nov;363(2):253-264. doi: 10.1124/jpet.117.242925. Epub 2017 Aug 29. PMID: 28851764.

In vitro protocol:

In vivo protocol:

1: Nishiyama K, Suzuki H, Harasawa T, Suzuki N, Kurimoto E, Kawai T, Maruyama M, Komatsu H, Sakuma K, Shimizu Y, Shimojo M. FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia. J Pharmacol Exp Ther. 2017 Nov;363(2):253-264. doi: 10.1124/jpet.117.242925. Epub 2017 Aug 29. PubMed PMID: 28851764.